Terns Pharma (NASDAQ:TERN) Azioni

TERNS PHARMACEUTICALS INC

Terns Pharma

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.

Equities

News

Movers

TERN

Il nuovo farmaco TERN-601 mostra risultati promettenti nella perdita di peso in sole 4 settimane con dosi giornaliere.

Nuovo farmaco promette di far perdere peso in sole 4 settimane

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharmaceuticals Inc

Tern PLC

TERNIUM ARGENTINA S A by TERNIUM ARGENTINA S A

Terna Energy SA

Terna Energy SA ADR

TRASMISSIONE ELECTR ORD by Terna Rete Elettrica Nazionale SPA

Terna SpA

TERNA RETE ELETTRICA ADR by Terna Rete Elettrica Nazionale SPA

Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares, USD1.00 par value)

Ternium SA

Ternoa

Rosenblatt analyst Barton Crockett maintains Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) with a Buy and raises the price target from $18 to $39.

Price Target

Analyst Ratings

MGNI

Rosenblatt Maintains Buy on Magnite, Raises Price Target to $39

Cryptocurrency markets are trading flat on Monday morning, with the Fear and Greed Index at a neutral 52, according to data by CoinMarketCap.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
</tr>
<tr>
<td>Bitcoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$107,795.52</td>
</tr>
<tr>
<td>Ethereum</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,461.70</td>
</tr>
<tr>
<td>Solana</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$150.49</td>
</tr>
<tr>
<td>XRP</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.17</td>
</tr>
<tr>
<td>Dogecoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1650</td>
</tr>
<tr>
<td>Shiba Inu</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001146</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin and Ethereum large transaction volume decreased by 7% and 11.5%, respectively. Daily active addresses for BTC and ETH were down by 10.5% and 2.4%, respectively.</li>
<li>Coinglass data shows 84,098 traders were liquidated in the past 24 hours for $208.35 million.</li>
<li>SoSoValue data shows net inflows of $501.27 million into spot Bitcoin ETFs on Friday, while spot Ethereum ETFs saw net outflows of $77.45 million.</li>
</ul>
Trader Notes: Crypto trader Jelle highlighted that Bitcoin is just hours away from securing a record-breaking monthly close. After taking out January's highs last month, BTC retested and held them this month, setting the stage for a potentially more bullish July.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">17 hours away from locking in another record-breaking monthly close. Broke the January highs last month &#8211; retested them this month, and pushed higher once more. July should be even better.<a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> <a href="https://t.co/UAsHi9Vt5Q">pic.twitter.com/UAsHi9Vt5Q</a>
&mdash; Jelle (@CryptoJelleNL) <a href="https://twitter.com/CryptoJelleNL/status/1939578495375450549?ref_src=twsrc%5Etfw">June 30, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trader Posty <a href="https://x.com/PostyXBT/status/1939609091342504081">said</a> Bitcoin remains in a consolidation range, dubbed "summer chop season," between $98,000 and $110,000. A close below $98,000 would signal bearish structure, while a breakout above $110,000 would confirm entry into new price discovery territory.
Despite the sideways action, BTC just posted its second-highest weekly candle close ever. Posty says bears are ignoring the underlying bullish strength and may soon face the consequences.
Crypto trader Coinvo <a href="https://x.com/ByCoinvo/status/1939625458548502652">sees</a> Ethereum following a classic Wyckoff accumulation pattern. If the structure holds, ETH is likely gearing up for a major breakout and new highs in the near term.
Rose Premium Signals <a href="https://x.com/VipRoseTr/status/1939382108642029806">noted</a> XRP is consolidating in a bullish pennant just under a multi-year supply zone. With the SEC lawsuit finally resolved, sentiment is shifting. A confirmed breakout could trigger a run toward the $5 mark.
Crypto Rand <a href="https://x.com/crypto_rand/status/1939612905567125865">pointed</a> to Solana breaking above its long-term downtrend resistance. If SOL can now reclaim and hold the $161 level, it would confirm a full bullish reversal, opening the door to stronger momentum.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46149584/why-crypto-investors-are-receiving-internal-revenue-service-warning-letters">Why Crypto Investors Are Receiving Internal Revenue Service Warning Letters</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Start Monday Flat As Traders Hope For Bullish July

WIIM

WBUY

Webuy Global shares are trading higher after the company integrated Coinbase to accept stablecoin payments.

Sonim Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>), a leading provider of rugged mobile solutions, today issued an update regarding the Letter of Intent (LOI) for a proposed reverse takeover (RTO), as originally announced via press release dated <a href="https://api.newsfilecorp.com/redirect/A85WPsvkxG">June 25, 2025</a>. The RTO is with a private US-based company (the "Target") that is building out Nvidia-based High-Performance Computing (HPC) AI factories to support the hyper growth of cloud-based artificial intelligence (AI) workloads.
Under the LOI, upon completion, Sonim shareholders will receive equity ownership in the combined company. While this equity ownership is currently valued at $17.5 million, Sonim shareholders will benefit from any future value appreciation of the combined entity.

SONM

Sonim Technologies Issues Update On Proposed Reverse Takeover With Nvidia-Based High-Performance Computing AI Factories

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SunCar Technology Expands Strategic Partnership With Xiaomi To Power Fully Intelligent Auto Insurance For YU7

<ul>
<li>BridgeBio has received a $300 million upfront payment, strengthening the Company's balance sheet, and supporting the launch of Attruby&#xAE; and ongoing late-stage pipeline programs</li>
<li>Transaction monetizes 60% of BridgeBio's European royalties on the first $500 million of annual BEYONTTRA net sales, with total payments to the investors subject to an initial cap of 1.45x</li>
<li>In the ATTRibute-CM study, acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date in both ATTRv-CM and ATTRwt-CM patients:
<ul>
<li>In as few as 3 months, the time to first event (ACM or CVH) durably separated relative to placebo</li>
<li>A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30</li>
<li>A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30</li>
</ul>
</li>
<li>Acoramidis is approved as Attruby by the U.S. FDA and is approved as BEYONTTRA by the European Commission, Japanese Pharmaceuticals and Medical Devices Agency and UK Medicines and Healthcare Products Regulatory Agency</li>
</ul>

BBIO

BridgeBio Sells Portion Of Royalties From BEYONTTRA Sales In Europe To Blue Owl Capital For $300M

ABEO

Abeona Therapeutics Added To Russell 2000 And Russell 3000 Indexes Following ZEVASKYN FDA Approval

FTI Consulting Appoints Christopher Allen To Lead Payments Modernization Efforts Within Financial Services Practice

<ul>
<li>In the Phase 2 MINDFuL trial of XPro in patients with early Alzheimer's Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary cognitive endpoint (EMACC), however in a predefined population of amyloid-positive early AD patients with two or more biomarkers of inflammation (n=100), a benefit of XPro&#x2122; treatment over placebo was observed in cognitive, behavioral and biological endpoints.</li>
<li>Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients. The most common adverse events (AE) were injection site reactions.</li>
<li>Additional analyses will be presented at Alzheimer's Association International Conference (AAIC) in Toronto, Canada (July 27-31, 2025) and the Company will submit for Breakthrough Therapy designation with the FDA.</li>
</ul>

Biotech

Health Care

General

INMB

INmune Bio Says Phase 2 MINDFuL Trial Evaluating XPro In Early Alzheimer's With Biomarkers Of Inflammation Did Not Meet The Primary Cognitive Endpoint

PVLA

Palvella Therapeutics Added To Russell 3000 Index And Russell 2000 Index, Effective June 30, As Part Of 2025 Russell Indexes Reconstitution

SunCar Technology Group Says Expects Business With Xiaomi To Double In 2025

Marex Group Added To Russell 3000 Index And Russell 2000 Index, Effective June 30, 2025, As Part Of 2025 Russell Indexes Reconstitution

Diginex Limited ("Diginex" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>), a leading provider of Sustainability RegTech solutions, today announced additional government funding support for its innovative AI-powered compliance solutions. Diginex's AI-powered compliance solutions will continue to focus on helping companies comply with sustainability disclosure requirements set by the International Sustainability Standards Board (ISSB) and International Financial Reporting Standards (IFRS) and now with the enhanced scope of AI-powered compliance solutions will additionally offer features including multi-variant drafts, risk reduction through automation, future-proofing against new regulations as well as enhanced scalability for users of the Company's ESG SaaS reporting product, diginexESG. Diginex's expanded AI features will streamline ESG reporting processes, thereby empowering businesses and financial institutions to meet regulatory requirements efficiently while driving transparency in corporate social responsibility and climate action, and will be jointly developed with a leading financial institution through a co-creation collaboration model promoting commercialisation and wider adoption.
The upgraded AI functionality of Diginex's AI-powered compliance solutions is expected to further accelerate customer adoption, and thereby, contribute to Diginex's revenue growth in 2025 and beyond. Industry research from Verdantix forecasts that the&nbsp;global market spend on ESG reporting software will grow from over $1.3 billion in 2023 to over $5.6 billion in 2029, at a CAGR of 26%. Diginex is well-positioned to capture this opportunity, combining its award-winning platform with blockchain, machine learning, and data analytics to deliver unparalleled value to clients worldwide.

DGNX

Diginex Announces Additional Government Funding Support For AI-Powered Compliance Solutions

PSTV

Plus Therapeutics Announces Initiation Of ReSPECT-LM Dose Optimization Trial For REYOBIQ

<ul>
<li>Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)</li>
<li>There are currently no therapies specifically approved for PMN, a rare immune-mediated disease affecting the kidneys with an estimated prevalence of ~36k patients in the U.S.</li>
<li>Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of immune-mediated diseases &nbsp;</li>
</ul>
CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=xpucNuq5lSnYJgRfRzFrTtFin8SCqxz8Dbc87J1HdvS90khSiKrbBzKE3mm7pEadONRZSUo7cBlQl8mCBmkg_w==">Biogen</a> Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary membranous nephropathy (PMN). PROMINENT is designed to enroll approximately 180 adults with PMN and expected to readout in 2029. PMN is a severe antibody-mediated disease of the kidney that is a leading cause of nephrotic syndrome and carries a significant risk of kidney failure.
Felzartamab is an anti-CD38 antibody that has been shown in clinical studies to selectively deplete CD38+ cells, including plasma cells, the source of autoantibodies that mistakenly attack the body's own tissues in a range of immune-mediated diseases. Importantly for felzartamab, it is estimated that up to 80% of PMN patients have autoantibodies against PLA2R (aPLA2R) generated by CD38-expressing plasma cells. Currently, there are no approved treatments for PMN and the standard of care includes treatments ranging from immunosuppressants to chemotherapy.

BIIB

Biogen Initiates Dosing In Global Clinical Study, PROMINENT, For Treatment Of Primary Membranous Nephropathy

Contracts

V2X Awarded Foreign Military Sales Contract To SupportIraq's F-16 Program; Initial Contract Value $118M

UNCY

Trading Halt: Halt status updated at 7:30:00 AM ET: Quotation Resumption: News and Resumption Times

BA early up move confirmed by TradePulse Order Flow Analytics
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27211217/Screenshot-2025-06-27-at-5.11.49%E2%80%AFPM-988x1024.png" alt="" class="wp-image-15037" /></figure>
Boeing Co. (BA) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 11:18 AM on June 27th, a significant trading signal occurred for Boeing Co. (BA) as it demonstrated a Power Inflow at a price of $209.02. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Boeing's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Boeing's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for BA,<a href="https://benzinga.grsm.io/register174"> Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like<a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025"> https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025</a>, which are responsible for parts of the data within this article.
After Market Close UPDATE:
The price at the time of the Power Inflow was $209.02. The returns on the High price ($214.81) and Close price ($214.55) after the Power Inflow are respectively 2.8% and 2.6%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. They were close today but that is not always the case
Past performance is not indicative of future results

Technicals

Opinion

Signals

Trading Ideas

Boeing Rises 2.8% After Key Trading Signal

D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) with a Buy and maintains $6 price target.

CTXR

D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Maintains $6 Price Target

FOXO

FOXO Technologies' Myrtle Recovery Centers Approved To Receive Scott County Opioid Abatement Funds For Second Year To Provide Care For Uninsured Patients From Scott County, At Oneida, Tennessee

Press Releases

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

Earnings

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

Comments

Terns Pharma

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO